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This study examined health status decline in patients with chronic
obstructive pulmonary disease (COPD). Data are from the Inhaled
Steroids in Obstructive Lung Disease (ISOLDE) trial. After an 8-wk
run-in, 751 patients (566 male), mean age 64 yr, were randomized
to receive fluticasone propionate (FP) 500 
 
m
 
g twice daily (376 pa-
tients) or placebo (375 patients). Mean baseline postbronchodila-
tor FEV
 
1
 
 was 50 
 
6
 
 15% predicted. Patients completed the St
George’s Respiratory Questionnaire (SGRQ) and the Short-Form
36 (SF-36) at baseline and every 6 mo for 3 yr. FEV
 
1
 
 and smoking
status were assessed at baseline and at 3-mo intervals. A total of
387 (212 FP) patients completed the trial. All SGRQ components
(p 
 
5
 
 0.03 to 0.004) and Physical Function, Mental Health, Energy/
Vitality, and Physical Role Limitation scales of the SF-36 (p 
 
5
 
 0.05
to 0.005) deteriorated faster in the placebo group. FEV
 
1
 
 and SGRQ
scores correlated at baseline values (r 
 
5
 
 
 
2
 
0.25, p 
 
,
 
 0.0001), as did
change in FEV
 
1
 
 and change in SGRQ (
 
D
 
 r 
 
5
 
 
 
2
 
0.24, p 
 
,
 
 0.0001). At
baseline values smokers had worse SGRQ Total, Symptoms, and
Impacts scores than ex-smokers. This difference was maintained
throughout the study. Smoking status did not influence the rate of
decline in health status. The SGRQ Total scores of FP-treated pa-
tients took 59% longer than placebo to deteriorate by a clinically
significant amount. We conclude that health status decline in mod-
erate to severe COPD can be reduced by high-dose fluticasone.
 
An accelerated decline of FEV
 
1
 
 is well-documented in patients
with chronic obstructive pulmonary disease (COPD). Although
FEV
 
1
 
 is a useful measure for diagnosis and prognosis, it is nei-
ther a good predictor of the symptomatic response to treat-
ment in COPD (1) nor of the likelihood of hospitalization (2).
This has led to the use of generic and disease-specific question-
naires to measure the impact of COPD on health status. Cross-
sectional studies have shown that patient populations with a
lower FEV
 
1
 
 have worse health-related quality of life (3). How-
ever, to our knowledge there are no data concerning the rate of
change in health status within patients over time.
We hypothesized that decline in health status would be de-
tectable in a population of patients in whom COPD was the
principal pathology and that this would be amenable to treat-
ment. All components of the disease-specific St George’s Re-
spiratory Questionnaire (SGRQ) have shown sensitivity to
impaired health in COPD (4). The physical function compo-
nents of the generic Short-Form 36 (SF-36) have demon-
strated sensitivity to change in COPD and to treatment with
fluticasone in severe asthma (5, 6) so we expected these com-
ponents of the SGRQ and SF-36 to show the greatest sensitiv-
ity to change in our study. Because it is known that smoking
has an effect on rate of decline in FEV
 
1
 
, we also hypothesized
that smoking status would influence health status and its rate
of deterioration. We used data collected as part of the Inhaled
Steroids in Obstructive Lung Disease (ISOLDE) study of flu-
ticasone in COPD. The intention-to-treat analyses of the prin-
cipal outcomes of this trial are reported elsewhere (7). For this
analysis, health status was measured using a generic instru-
ment, the SF-36 and a disease-specific instrument, the SGRQ.
 
METHODS
 
Patients
 
Full details of the study methodology, patient selection, and spiromet-
ric procedures are presented elsewhere (7). Seven hundred fifty-one
patients (560 men) with a diagnosis of COPD consistent with Ameri-
can Thoracic Society (ATS) recommendations (8) were recruited from
18 centers throughout the United Kingdom. All were current or ex-
smokers age 40 to 75 yr with a postbronchodilator FEV
 
1
 
 of at least 0.8 L,
but less than 85% predicted. The FEV
 
1
 
/FVC ratio was less than 70%.
 
Exclusion criteria were: an FEV
 
1
 
 response to 400 
 
m
 
g salbutamol of
 
.
 
 10% predicted; use of 
 
b
 
-adrenergic blockers; use of nontrial inhaled
corticosteroids or regular oral corticosteroid; a life expectancy of less
than 5 yr from non-COPD diseases. At baseline values, postbroncho-
dilator FEV
 
1
 
 expressed as percent of predicted normal was 50 
 
6
 
 15
(SD)%. The mean FEV
 
1
 
 response to salbutamol was 4.4% predicted
(0.13 L). During the study, patients requiring long-term treatment
with oral corticosteroids or more than two short courses of treatment
in any 3-mo period were withdrawn. Ethical committee approval was
obtained in each participating center and informed consent was ob-
tained before entry to the study.
 
Health Status Measurement
 
General Health Status was assessed using the SF-36 (9), a generic
measure of health impairment (10). It is a self-completed question-
naire containing 36 questions covering eight health concepts: Physical
Function, Physical Role Limitation, Mental Role Limitation, Social
Function, Mental Health, Pain, Energy/Vitality, and Health Percep-
tion. Two summary components (Physical and Mental) can also be
calculated by differentially weighting the scales. The SF-36 scales are
scored as a percentage of impairment with zero representing worst
health and 100 indicating best health. With this scale, a decrease in
score indicates worsening general health. Its reliability is extensively
documented (11).
The SGRQ (12) is a supervised, self-administered measure de-
signed specifically for use in airways disease. It is a 50-item survey
from which are calculated the Total and three component scores:
Symptoms (distress caused by respiratory symptoms), Activity (physi-
cal activities that cause or are limited by breathlessness), and Impacts
(social and psychological effects of the disease). The SGRQ is scored
from zero to 100, where zero indicates best health and 100 indicates
worst health. A change in score of four units is consistent with a clini-
cally significant change in the patient. This estimate was made in pa-
tients with a similar degree of airway obstruction and level of SGRQ
score to patients recruited to this study (4, 13). An increase in score
indicates worsening health status. The SGRQ has been shown to be a
valid measure of health impairment in chronic airflow limitation and
to respond to change with therapy (1, 12, 14).
Normative values for SF-36 were taken from the Oxford Healthy
Life Survey (15). These were subjects with a mean age of 51 yr (SD 7
yr) who did not report a chronic illness or a medical consultation in
the 2 wk before assessment. The SGRQ control scores were obtained
from a study of healthy subjects age 17 to 80 with no current or previ-
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ous history of chest disease who were free of viral upper respiratory
tract infection. For this comparison, scores from a cohort of this sam-
ple in the same age range as ISOLDE patients were used. Their mean
age was 60 yr (SD 12 yr).
 
Spirometry
 
Spirometry was measured according to ATS criteria for acceptability
and reproducibility (16) using a computerized rolling-seal spirometer
(SensorMedics 2130D, Netherlands). All FEV
 
1
 
 measurements re-
ported here were obtained postbronchodilator.
 
Protocol
 
Patients entered an 8-wk run-in period during which any current in-
haled corticosteroid treatment was discontinued. Postbronchodilator
spirometry was assessed at 0, 4, and 8 wk. Patients were offered 14 d
treatment with oral prednisolone 0.6 mg/kg/d. They were then ran-
domized to enter a 3-yr double-blind comparison of inhaled flutica-
sone propionate (FP) 500 
 
m
 
g or matched placebo twice daily via me-
tered-dose inhaler and spacer. The SGRQ and SF-36 were completed
after the run-in at 8 wk and then at 6-mo intervals for 3 yr. Patients
completed questionnaires on the same day that lung function was
tested. Both questionnaires were completed under the supervision of
clinical staff and according to guidelines in the relevant manuals. Clin-
ical staff received training on questionnaire administration. Question-
naires were monitored for missed items throughout the study and re-
ports sent to each center every 6 mo.
Smoking history was evaluated using the Medical Research Coun-
cil bronchitis questionnaire at baseline values and self-reported smok-
ing status recorded 3 mo thereafter. This was confirmed by measure-
ment of exhaled carbon monoxide and urinary cotinine. Details of the
evaluation of smoking status have been reported previously (7). Pa-
tients who continued to smoke throughout the study (38%) were de-
fined as smokers (Placebo 147, FP 137). Patients who had not smoked
during the study (46%) were defined as ex-smokers (Placebo 172, FP
176), and 16% were mixed smokers who had either resumed smoking
or had quit during the study (Placebo 56, FP 63).
 
Statistical Analysis
 
The purpose of the study was to compute the rate or velocity of de-
cline in health status. The SGRQ and SF-36 scores were calculated us-
ing the methods documented in their respective manuals. This in-
cluded handling of individual missing questionnaire items. Because
there were significantly more patients in the placebo group who failed
to complete the study than FP-treated patients (7), the rate of decline
had to be calculated using a method that took into account this differ-
ential drop-out pattern. A random coefficients hierarchical model was
used, in which the regression estimates were weighted by the number
of observations and the amount of variance contributed by each pa-
tient (17). Patients who did not complete the study contributed less
weight to the model than those who did complete. Nonlinearity in the
slopes was tested by fitting a quadratic term for time. The intention-
to-treat population was used for the comparison of FP against pla-
cebo. In that analysis, covariates in the model included baseline health
status score, smoking status during the study, sex, age at baseline, and
study center. These covariates were entered as fixed effects. Slopes
were allowed to vary between patients, so time was entered as a ran-
dom effect. Differences in rate of deterioration between the treat-
ment and placebo groups were tested using a treatment-by-time inter-
action term. Baseline health status score was used as a covariate in the
model, so the rate of decline was estimated using data from the 6-mo
assessment onward, to a maximum of 6 assessments per subject. The
numbers of patients included in each analysis varied, owing to patient
withdrawal or missing data.
The principle hypotheses to be tested were: (
 
1
 
) Health status
would decline more slowly in patients treated with FP compared with
placebo. (
 
2
 
) Smokers would have worse health status than ex-smokers
and their rate of decline in health status decline would be higher than
ex-smokers. (
 
3
 
) Baseline FEV
 
1
 
 percentage of predicted would be re-
lated to baseline health status but would not predict health status de-
cline. (
 
4
 
) Health status decline and FEV
 
1
 
 decline would be correlated.
 
RESULTS
 
We received over 3,500 completed versions of each question-
naire; less than 4% of the questionnaires were not returned,
i.e., were classified as missing data. The number of SGRQ and
SF-36 questionnaires collected at each measurement occasion
are shown in Table 1. There were 387 patients remaining in
the study at the end of 36 mo.
 
Baseline Health Status
 
All baseline SGRQ scores were higher than scores from the
reference population, indicating that these patients had worse
health compared with normal subjects (Table 2). Baseline SGRQ
Total, Symptoms, and Activity scores were not different be-
tween treatment groups (Table 2) although the baseline Im-
pact score was marginally worse in the placebo group com-
pared with FP (p 
 
5
 
 0.03). The baseline scores for the physical
components of the SF-36 were lower than healthy subject scores
(indicating worse health status) and did not differ between FP
and placebo groups. In contrast, the baseline SF-36 Mental
Health and Mental Summary scores were only slightly lower than
those in normal subjects. The baseline score for Mental Health
was worse in the placebo group compared with FP (p 
 
5
 
 0.04).
Worse baseline health status was associated with lower
baseline FEV
 
1
 
. All correlations between baseline SGRQ scores
and baseline FEV
 
1
 
 percentage of predicted were low, but sta-
tistically significant (r 
 
5
 
 
 
2
 
0.12 to 
 
2
 
0.31, p 
 
,
 
 0.01 to p 
 
,
 
0.0001). The SF-36 Physical Function, Physical Role Limita-
tion, Physical Summary, Social Function, and Health Percep-
tion scores were significantly related to baseline FEV
 
1
 
 values
(r 
 
5
 
 0.15 to 0.25, p 
 
,
 
 0.001 to p 
 
,
 
 0.0001), again showing that
a lower FEV
 
1
 
 was related to worse general health.
 
Change in Health Status in the First 6 mo
 
Over this period, the SGRQ Activity score improved slightly
in the FP group and worsened in the placebo group (
 
D
 
 FP 
 
5
2
 
0.2; 
 
D
 
 Placebo 
 
5
 
 
 
1
 
2.7: p 
 
5
 
 0.03). Changes in the other
SGRQ scores and the SF-36 scores over the same period were
not significant. The change in SGRQ Total score from base-
line to 6 mo is shown in Figure 1.
 
Deterioration in Health Status Over 3 yr
 
Health status declined progressively in all components of the
SGRQ (p 
 
,
 
 0.0001) and in all components of the SF-36 (p 
 
,
 
0.001). The rate of deterioration in health status was linear
with no significant polynomial component in any score.
The SGRQ Total score worsened by 2.0 units per year in
the FP-treated group and by 3.2 units per year in the placebo
group (Table 3). FP reduced the rate of deterioration in the
Total score by 37% compared with placebo (p 
 
5
 
 0.004). The
greatest effect of treatment was seen in the Symptoms compo-
 
TABLE 1
NUMBER OF QUESTIONNAIRES RECEIVED*
 
SGRQ SF-36 Patients in the Study (FP)
Baseline 736 732 751 (376)
6 mo 608 610 624 (320)
12 mo 534 530 548 (289)
18 mo 490 488 506 (267)
24 mo 449 452 468 (252)
30 mo 412 410 424 (232)
36 mo 368 364 394 (212)
Total received 3,597 3,586
Not received (%) 122 (3.3) 133 (3.7)
* Unequal numbers are due to patients attending visits but not completing question-
naires. Declining numbers over time are due to patients withdrawing from the study.
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nent of the SGRQ in which FP significantly reduced the rate
of deterioration in scores by 56%. FP reduced the rate of de-
cline in Activity scores by 39% and in Impacts scores by 33%
compared with placebo (Figure 2). The SGRQ Total score in
the placebo group took 1.26 yr (approximately 15 mo) to dete-
riorate by the minimal clinically important difference of 4 units,
compared with 2.00 yr in the FP group (Figure 2).
Fluticasone significantly reduced the rate of deterioration
in SF-36 scores for Physical Function, Energy/Vitality, and
Physical Role Limitation (Table 4); however, the Physical Sum-
mary score which summarizes all SF-36 components related to
physical impairment was not influenced by treatment (Figure
2). Of the psychosocial components, only the deterioration in
Mental Health scores was significantly different between treat-
ments. In the FP-treated patients, this score did not change,
but the placebo-treated patients showed a significant deterio-
ration. The deterioration in Mental Role Limitation, General
Health Perception, Social Function, Pain, and Mental Sum-
mary scores was not significantly different between FP and
placebo. No minimal clinically important difference value has
been established for the SF-36 in patients with COPD, so the
clinical significance of these scores cannot be assessed.
 
Influence of Baseline FEV
 
1
 
 on Health Status Deterioration
 
A lower FEV
 
1
 
 at baseline was associated with a more rapid
rate of decline in SGRQ Impacts scores (p 
 
5
 
 0.008). There
were no significant differences in this relationship between
treatment groups (p 
 
.
 
 0.05). There was no significant rela-
tionship between baseline FEV
 
1
 
 and the rate of decline in the
SGRQ Total, Symptoms, or Activity scores (p 
 
.
 
 0.05). There
was no significant relationship between baseline FEV
 
1
 
 and the
rates of decline in any of the SF-36 scales (p 
 
.
 
 0.05).
 
Influence of Smoking on Baseline Health Status
 
Analysis was restricted to those who either smoked for the du-
ration of the study or who remained ex-smokers throughout.
Smokers had worse baseline SGRQ scores than ex-smokers:
Total (difference 
 
5
 
 3.6, p 
 
5
 
 0.04), Symptoms (difference 
 
5
 
9.7, p 
 
,
 
 0.0001), and Impacts (difference 
 
5
 
 4.7, p 
 
5
 
 0.01). The
baseline Activity scores did not differ by smoking status.
Smokers had worse baseline SF-36 scores than ex-smokers for
Mental Health (difference 
 
5
 
 
 
2
 
5.1, p 
 
5
 
 0.003), Mental Role
Limitation (difference 
 
5
 
 
 
2
 
10.8, p 
 
5
 
 0.007), Mental Summary
(difference 
 
5
 
 
 
2
 
3.6, p 
 
5
 
 0.0004), Health Perception (differ-
ence 
 
5
 
 
 
2
 
4.8, p 
 
5
 
 0.02), Energy/Vitality (difference 
 
5
 
 
 
2
 
6.1, p 
 
5
 
0.002), and Pain (difference 
 
5
 
 
 
2
 
6.2, p 
 
5
 
 0.02). There were no
significant differences between the baseline scores of smokers
and ex-smokers on any of the remaining scales: Physical Func-
tion, Physical Role Limitation, Physical Summary, and Social
Function. Multivariate analysis showed that differences in health
status between current and ex-smokers were not attributable
to differences in FEV
 
1
 
.
Figure 1. Change in SGRQ Total score over the first 6 mo of treatment
for placebo-treated patients (squares) and FP-treated patients (circles).
Higher SGRQ score indicates worse health. Bars represent 95% confi-
dence intervals.
 
TABLE 3
DIFFERENCE IN SGRQ RATES OF DETERIORATION
BETWEEN FP AND PLACEBO*
 
n
FP
(
 
Units/yr
 
)
(SE)
Placebo
(
 
Units/yr
 
)
(SE)
FP-Placebo
Difference
(95% CI) p Value
Total 600 2.00 3.17
 
2
 
1.17 0.004
(0.29) (0.31) (
 
2
 
0.39, 
 
2
 
1.95)
Symptoms 600 1.02 (0.37) 2.33
 
2
 
1.31 0.007
(0.40) (
 
2
 
0.37, 
 
2
 
2.25)
Activity 600 2.10 (0.35) 3.47
 
2
 
1.37 0.004
(0.38) (
 
2
 
0.45, 
 
2
 
2.29)
Impacts 600 2.17 (0.36) 3.24
 
2
 
1.07 0.03
(0.38) (
 
2
 
0.11, 
 
2
 
2.03)
* The higher the slope, the greater the rate of declilne of health status.
 
TABLE 2
HEALTHY SUBJECT AND BASELINE ISOLDE PATIENT SCORES
 
Healthy Subjects
(
 
mean
 
 
 
6
 
 
 
SD
 
)
Placebo
(
 
mean
 
 
 
6
 
 
 
SD
 
)
FP
(
 
mean
 
 
 
6
 
 
 
SD
 
)
Placebo 
 
2
 
 FP
Difference
(
 
p Value)
SGRQ
Total 7 6 7 50 6 17 48 6 18 0.08
Symptoms 12 6 15 67 6 22 66 6 21 0.5
Activity 11 6 13 62 6 21 61 6 22 0.4
Impact 3 6 5 38 6 19 35 6 19 0.03
SF-36
Physical function 91 6 13 40 6 26 44 6 25 0.09
Mental health 78 6 16 70 6 18 73 6 18 0.04
Energy/Vitality 66 6 18 46 6 21 48 6 20 0.3
Health perception 79 6 15 40 6 21 42 6 20 0.1
Physical role limitation 93 6 20 40 6 42 44 6 41 0.1
Mental role limitation 89 6 26 59 6 43 63 6 42 0.2
Social function 94 6 14 69 6 28 71 6 27 0.3
Pain 88 6 16 73 6 27 74 6 27 0.6
Physical summary 55 6 5 35 6 10 36 6 10 0.2
Mental summary 53 6 6 49 6 11 50 6 10 0.06
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Figure 2. Slope of deterioration in health
status calculated using estimates from a ran-
dom coefficients hierarchical model. The re-
gression estimates are weighted by the num-
ber of observations and the variance contributed
by each patient. A higher SGRQ score or a
lower SF-36 score indicates worse health sta-
tus. All SGRQ component scores are shown,
together with selected SF-36 scores.
Influence of Smoking on Health Status Deterioration
The differences between smokers and ex-smokers observed
in the SGRQ components at baseline values were maintained
throughout the study. The mean difference in score between
smokers and nonsmokers over three yr was: Total 4.3 (p 5
0.002); Symptoms 5.4 (p 5 0.0001); Impacts 5.6 (p 5 0.0005).
The Activity score remained not different between the two
groups (p 5 0.8). Smoking status had no effect on the rate of
deterioration in SGRQ score, i.e., smokers and ex-smokers
declined in parallel (Figure 3). Smoking had no influence on
the effect of FP on decline in health status.
Differences in the three SF-36 mental health scores be-
tween smokers and ex-smokers at baseline were maintained
throughout the study (p , 0.05). On average Social Function
scores were worse in smokers during the study period, al-
though there was no significant difference at baseline. There
were no differences in the rate of deterioration of SF-36 scores
between smokers and ex-smokers, neither did smoking status
influence the effect of FP on change in health status.
Relationship between Health Status Decline
and the Rate of Decline in FEV1
Details of changes in FEV1 during the study have been re-
ported elsewhere (7). The current analysis showed that there
was a small but significant linear relationship between the rate
of decline in SGRQ scores and rate of decline in FEV1: Total 5
R 20.24, p , 0.0001; Symptoms 5 R 20.14, p 5 0.0005; Activ-
ity 5 R 20.25, p , 0.0001; Impacts 5 R 20.18, p , 0.0001.
There was a similar relationship between the rate of decline in
the physical components of the SF-36 and the rate of decline
in FEV1: Physical Function 5 R 0.22, p , 0.0001; Physical
Role Limitation 5 R 0.12, p 5 0.005; Energy/Vitality 5 R
0.15, p 5 0.0003; Health Perception 5 R 0.15, p 5 0.0003;
Physical Summary 5 R 0.21, p , 0.0001. Rates of decline in
the Pain scale and the psychosocial components of the SF-36
(Mental Health, Mental Role Limitation, Social Function, and
Mental Summary) were unrelated to the rate of decline in
FEV1 (p . 0.05). The relationship between health status de-
cline and FEV1 decline did not differ between treatments (p .
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0.01) or by smoking status (p . 0.01) on any of the compo-
nents of the SGRQ or the SF-36.
DISCUSSION
We have found clear evidence of a measurable and progres-
sive deterioration in the health of this population of patients
with COPD. This was present in all domains of health impair-
ment: symptoms, physical activity, and psychosocial function,
whether measured using the disease-specific SGRQ or the ge-
neric SF-36. Previous studies have measured change in health
status by comparing baseline to endpoint values (1, 12) but few
have assessed change using more than two measurement points.
Other trials have measured health status on multiple occa-
sions but have design limitations such as small sample size
(18), sole use of a generic measure (19), or use of a relatively
untested generic measure on a male-only population (5). This
is the first published study to document health status decline
prospectively in a large and well-characterized population.
Particular care was taken to establish a cohort of stable pa-
tients with COPD without substantial comorbidity that might
confound the health status assessments. These patients appear
to be similar to other populations of patients with COPD be-
cause the mean value for FEV1 and mean SGRQ Total score
measured at baseline in this study lie on a previously reported
regression between mean values for these two measures found
in other studies (20). The baseline health status scores for the
SGRQ showed substantial differences from scores in disease-
free subjects. Most of the SF-36 scores, with the exception of
Mental Health, were also significantly worse than in the con-
trol subjects.
The rate of deterioration in health status was reduced by
inhaled fluticasone. This effect was seen in all domains of
health measured using the SGRQ, and the SF-36 Physical Func-
tion, Physical Role Limitation, Energy/Vitality, and Mental
Health scales. As has been reported previously in patients
with COPD (1), the disease-specific questionnaire was more
sensitive to therapeutic intervention than the generic instru-
ment. Mechanisms responsible for the beneficial effect of in-
haled steroids have yet to be identified. Our data suggest that
it is an effect that accumulates over time because the differ-
ence in health of placebo- and fluticasone-treated patients
widened progressively. One possible mechanism is a link with
exacerbations. In this study, exacerbations that required treat-
ment with oral steroids or antibiotics were reduced by flutica-
sone (7) and patients with a high number of exacerbations
have been reported to have worse SGRQ scores than those
with few (21). In support of this hypothesis is the observation
that fluticasone exerted its greatest influence on the rate of
decline in the Symptoms component of the SGRQ. This ad-
dresses the impact of the frequency of episodes of wheeze,
cough, and sputum. In terms of consistency across health do-
mains, the drug had greatest influence on deterioration in
physical aspects of health rather than psychosocial functions.
This observation leads us to speculate that each exacerbation
may lead to a step reduction in physical activity and function
that may not be fully reversible. By reducing the number of
exacerbations, fluticasone would improve symptoms and re-
duce the rate at which physical function deteriorates.
Could drug-related euphoria account for the effect of fluti-
casone? Clinical observations of nonspecific improvements in
mood with high doses of oral corticosteroids led to their use in
palliative care, but well-controlled trials have not been re-
ported. Most reports of the psychological effects of oral corti-
costeroids have been concerned with major psychoses in pa-
tients receiving medium-high dose treatment (greater than
prednisolone 40 mg/d or equivalent). There has been only one
study of possible euphoriant effects of corticosteroids in pa-
tients with COPD (22). In that study, patients given oral pred-
nisolone 30 mg/d showed a very small improvement in anxiety
and depression after 1 wk of therapy, but those changes had
largely reversed after 2 wk despite continued steroid treat-
ment. Oral corticosteroids were given for 2 wk at the start of
our study, but this cannot explain the health status benefit of
fluticasone because both placebo- and fluticasone-treated pa-
tients received prednisolone. It is unlikely that there was any
carry-over effect of that treatment, because we found no evi-
dence of improved psychosocial function in either treatment
group over the first 6 mo of therapy. Finally, it should be
noted also that effects of fluticasone were most consistent in
the physical domains of health impairment, rather than the
psychological components. We conclude that there is no evi-
dence of a “euphoriant” effect of inhaled steroids in COPD.
Current smokers had worse health at baseline than ex-
smokers, a difference that was not attributable to differences
in FEV1. Reasons for this association are not clear from this
study, but it is noteworthy that the SGRQ Symptoms and
TABLE 4
DIFFERENCE IN SF-36 RATES OF DETERIORATION
BETWEEN FP AND PLACEBO*
n
FP
(Units/yr)
(SE)
Placebo
(Units/yr)
(SE)
FP 5 Placebo
Difference
(95% CI) p Value
Physical function 592 21.73 23.33 1.60 0.005
(0.43) (0.46) (0.50, 2.70)
Mental health 596 0.02 21.13 1.15 0.005
(0.34) (0.35) (0.35, 1.95)
Energy/vitality 596 21.20 22.38 1.18 0.02
(0.38) (0.41) (0.24, 2.12)
Physical role limitation 595 22.96 24.97 2.01 0.05
(0.87) (0.92) (0.03, 3.99)
Social function 582 22.55 24.03 1.48 0.06
(0.62) (0.67) (20.30, 2.99)
Pain 591 21.39 22.28 0.89 0.2
(0.57) (0.61) (20.50, 2.28)
Mental role limitation 599 24.51 25.56 1.05 0.4
(0.97) (1.04) (21.24, 3.34)
Health perception 568 22.33 22.77 0.44 0.4
(0.37) (0.40) (20.52, 1.40)
Physical summary 547 20.86 21.31 0.44 0.07
(0.19) (0.20) (20.03, 0.91)
Mental summary 547 20.66 21.14 0.48 0.09
(0.23) (0.24) (20.07, 1.03)
* The more negative the slope, the greater the rate of decline of health status.
Figure 3. Deterioration in SGRQ score in smokers and ex-smokers (see
Figure 2 for method of calculating slopes). Smokers had higher SGRQ
scores, i.e., worse health, at baseline. The rate of decline in smokers
and ex-smokers was parallel in both treatment arms. Within each treat-
ment group, smokers and ex-smokers declined at the same rate, i.e.,
smoking status did not influence the treatment effect.
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Impact scores and the SF-36 psychosocial scales were most
affected by smoking status. In contrast, neither the physically
oriented scales of the SF-36 nor the physical Activity compo-
nent of the SGRQ were related to smoking. Health status
declined at the same rate in smokers and ex-smokers, the dif-
ference between them neither widening nor narrowing signifi-
cantly. This is in contrast to the effect of smoking on decline in
FEV1 (7). The effect of fluticasone on the rate of deterioration
in health appeared to be the same in smokers and ex-smokers.
To explain these observations, two hypotheses appear equally
plausible: either patients with poor psychosocial status are less
able to quit smoking, or smoking makes these aspects of health
worse. There were too few patients who restarted or stopped
smoking during the study to test these hypotheses.
At baseline values there was a weak correlation between
FEV1 and SGRQ score. This was expected because weak cor-
relations between health status and spirometry have been re-
ported previously (3, 12, 23). In contrast, correlations between
health status and other physiological measures such as exer-
cise performance and arterial PO2 may be stronger (12, 23, 24).
An association between worse baseline FEV1 and subsequent
rate of decline of SGRQ Impacts score was an unexpected
finding. If confirmed in further studies it may suggest that
health status decline accelerates with worsening lung function.
Because cross-sectional studies (i.e., between patients) had
shown a significant correlation between FEV1 and health sta-
tus (3), the weak but significant correlation between decline in
FEV1 and decline in health status was expected. It is notewor-
thy that correlations between FEV1 and SGRQ score were of
similar strength whether between or within patients.
The clinical significance of the changes produced by our in-
terventions can be interpreted only for the SGRQ score be-
cause there is no defined clinically significant change score for
the summary components of the SF-36 when used in COPD.
The placebo-treated patients reached a clinically significant
level of deterioration of 4 units in SGRQ Total score (4, 13)
every 15 mo. Those receiving fluticasone took 24 mo to de-
cline by the same amount. To set these values into a clinical
context, it is necessary to “back-translate” a 4-unit change in
SGRQ score into patient scenarios. Two examples of what a
4-unit deterioration may mean to a patient are illustrated
here. Each should be seen as being a comparison with a previ-
ous assessment. Example 1: The patient now has to walk
slower than others of his or her age, has become breathless on
getting washed or dressed, and is now breathless on bending
over. Example 2: The patient now takes a long time to wash or
dress, can no longer walk up stairs without stopping, and can-
not now go out for entertainment. To achieve a 4-unit deterio-
ration in SGRQ, the patient must have experienced all three
components described in each scenario. It is quite clear that
the degree of deterioration illustrated by these two examples
would be quite significant in a patient’s life. This degree of
worsening occurs every 15 mo, but fluticasone increases the
time it takes for this to occur by 58%. This appears to be a
worthwhile therapeutic benefit.
This study has shown that it possible to measure the rate of
decline of health status in COPD and to detect worthwhile treat-
ment benefits; however, there are some limitations to the gen-
eralizability of the results. First, the entry criteria excluded
patients with COPD with a high level of bronchodilator re-
versibility, because we were anxious to exclude patients who
may be considered to be asthmatic. We believe that this entry
criterion was unlikely to have biased the study in favor of a
large treatment effect, however. Second, many patients who
entered the study had survived withdrawal from inhaled ste-
roids to enter the trial. A previous publication reported that
such patients had a higher number of exacerbations during the
run-in phase of the study than patients who were not with-
drawn from (25). As a result, possible “steroid-dependent”
patients did not enter the study and may have biased the result
toward an underestimate of the “true” steroid effect to be ob-
tained in COPD. Third, post hoc subgroup analysis (not re-
ported here) showed that patients who withdrew from the study
had a significantly higher rate of decline of health status than
those who completed the 3-yr treatment period. These pa-
tients also showed the greatest effect of FP compared with
placebo. The hierarchical statistical model used for this analy-
sis placed less weight on data from these patients because they
contributed fewer observations than patients who completed
the study. Overall, it appears that the patient entry criteria
and method of analysis may have led to a conservative esti-
mate of the effect of FP in patients with COPD.
This study has a number of implications for the treatment
of COPD and for clinical trials in this field. We have shown that
the health of patients with COPD patients treated with bron-
chodilator therapy alone deteriorates by a clinically significant
amount every 15 mo. This deterioration can be detected using
both disease-specific and generic measurements; however, the
former gave more consistent results and may be more sensi-
tive to change. Maintenance therapy with FP reduced the rate
at which deterioration progressed. This benefit, best seen in
the physical components of health, required time to accumu-
late. Continuing smokers had worse health than did patients
who had stopped, but it is not clear whether smoking cessation
is the cause for the better level of health. The ISOLDE study
has demonstrated that measuring health status is valuable in
long-term trials designed to establish whether therapy alters
progression of COPD.
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